Increased glutamine in patients undergoing long-term treatment for schizophrenia: A proton magnetic resonance spectroscopy study at 3 T

JAMA Psychiatry

Volumn 71, Issue 3, 2014, Pages 265-272

  Bustillo, Juan R ^a   Chen, Hongji ^a   Jones, Thomas ^a   Lemke, Nicholas ^a   Abbott, Christopher ^a   Qualls, Clifford ^a   Canive, Jose ^a   Gasparovic, Charles ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b MIND RESEARCH NETWORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; GLUTAMIC ACID; GLUTAMINE;

ANTERIOR CINGULATE; ARTICLE; BLOOD LEVEL; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DSM-IV-TR; HUMAN; IMAGE ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROTRANSMISSION; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA;

ADULT; CHOLINE; CROSS-SECTIONAL STUDIES; FEMALE; GLUTAMIC ACID; GLUTAMINE; GYRUS CINGULI; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROTONS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84896771002     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.3939     Document Type: Article

References (45)

1. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52(12):998-1007.
2. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37(1):4-15.
3. Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci. 1999;354(1387):1155-1163.
4. Iltis I, Koski DM, Eberly LE, et al. Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study. NMR Biomed. 2009;22(7):737-744.
5. Newcomer JW, Krystal JH. NMDA receptor regulation of memory and behavior in humans. Hippocampus. 2001;11(5):529-542.
6. Rowland LM, Bustillo JR, Mullins PG, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry. 2005;162(2):394-396.
7. Stone JM, Dietrich C, Edden R, et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry. 2012;17(7):664-665.
8. Pilowsky LS, Bressan RA, Stone JM, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry. 2006;11(2):118-119.
9. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull. 2013;39(1):120-129.
10. Mullins PG, Chen H, Xu J, Caprihan A, Gasparovic C. Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites. Magn Reson Med. 2008;60(4):964-969.
11. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14(4):260-264.
12. Ongür D, Jensen JE, Prescot AP, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry. 2008;64(8):718-726.
13. Shirayama Y, Obata T, Matsuzawa D, et al. Specificmetabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage. 2010;49(3):2783-2790.
14. Gasparovic C, Song T, Devier D, et al. Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn Reson Med. 2006;55(6):1219-1226.
15. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31(1):5-19.
16. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
17. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
18. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
19. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4):486-487.
20. Kraguljac NV, Reid M, White D, et al. Neurometabolites in schizophrenia and bipolar disorder: a systematic review and meta-analysis. Psychiatry Res. 2012;203(2-3):111-125.
21. Maudsley AA, Domenig C, Govind V, et al.Mapping of brainmetabolite distributions by volumetric proton MR spectroscopic imaging (MRSI). Magn Reson Med. 2009;61(3):548-559.
22. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167(6):686-693.
23. Stone JM, Day F, Tsagaraki H, et al; OASIS. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry. 2009;66(6):533-539.
24. Bartha R,Williamson PC, Drost DJ, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1997;54(10):959-965.
25. Tayoshi S, Sumitani S, Taniguchi K, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla protonmagnetic resonance spectroscopy (1H-MRS). Schizophr Res. 2009;108(1-3):69-77.
26. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-Daspartate receptor antagonists. Arch Gen Psychiatry. 2000;57(3):270-276.
27. Beckmann M, Johansen-Berg H, Rushworth MF. Connectivity-based parcellation of human cingulate cortex and its relation to functional specialization. J Neurosci. 2009;29(4):1175-1190.
28. Jensen J, Kapur S. Salience and psychosis: moving from theory to practise. Psychol Med. 2009;39(2):197-198.
29. Xu S, Yang J, Li CQ, ZhuW, Shen J. Metabolic alterations in focally activated primary somatosensory cortex of alpha-chloraloseanesthetized rats measured by 1H MRS at 11.7 T. Neuroimage. 2005;28(2):401-409.
30. Gluck MR, Thomas RG, Davis KL, Haroutunian V. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry. 2002;159(7):1165-1173
31. Matute C, Melone M, Vallejo-Illarramendi A, Conti F. Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia. 2005;49(3):451-455.
32. Yamasue H, Fukui T, Fukuda R, et al. 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. Neuroreport. 2002;13(16):2133-2137.
33. Urenjak J, Williams SR, Gadian DG, NobleM. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci. 1993;13(3):981-989.
34. Choi JK, Dedeoglu A, Jenkins BG. Application of MRS to mouse models of neurodegenerative illness. NMR Biomed. 2007;20(3):216-237.
35. Harrison PJ,Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;10(1):40-68, 5.
36. Selemon LD, Lidow MS, Goldman-Rakic PS. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol Psychiatry. 1999;46(2):161-172.
37. Konopaske GT, Dorph-Petersen KA, Pierri JN, Wu Q, Sampson AR, Lewis DA. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology. 2007;32(6):1216-1223.
38. Bustillo J, Barrow R, Paz R, et al. Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology. 2006;31(4): 751-756.
39. Olabi B, Ellison-Wright I, McIntosh AM,Wood SJ, Bullmore E, Lawrie SM. Are there progressive brain changes in schizophrenia? ameta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry. 2011;70(1):88-96.
40. Théberge J, Williamson KE, Aoyama N, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry. 2007;191:325-334.
41. Steen RG, Hamer RM, Lieberman JA. Measurement of brainmetabolites by 1Hmagnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology. 2005;30(11):1949-1962.
42. Gallinat J, Lang UE, Jacobsen LK, et al. Abnormal hippocampal neurochemistry in smokers: evidence from protonmagnetic resonance spectroscopy at 3 T. J Clin Psychopharmacol. 2007;27(1):80-84.
43. Freedman R, Adler LE, Bickford P, et al. Schizophrenia and nicotinic receptors. Harv Rev Psychiatry. 1994;2(4):179-192.
44. Théberge J, Bartha R, Drost DJ, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry. 2002;159(11):1944-1946.
45. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13(9):1102-1107.